

TDMs No. 20009 - 04

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 05/27/2011

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

F2_M3

C Number: C20009
Lock Date: 05/05/2008
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.4.1.0_004
PWG Approval Date: 12/14/2010

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
------------------	--------	------------	----------	-----------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	6	4	8	7
Natural Death	20	20	15	10
Survivors				
Terminal Sacrifice	24	26	27	33
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(36)	(33)	(39)	(42)
Intestine Large, Cecum	(35)	(34)	(36)	(40)
Intestine Large, Colon	(40)	(40)	(41)	(40)
Sarcoma, Metastatic, Liver		1 (3%)		
Intestine Large, Rectum	(39)	(38)	(42)	(41)
Intestine Small, Duodenum	(36)	(31)	(35)	(40)
Adenoma				1 (3%)
Intestine Small, Ileum	(36)	(35)	(39)	(40)
Intestine Small, Jejunum	(35)	(32)	(37)	(40)
Adenoma		1 (3%)		1 (3%)
Carcinoma	2 (6%)	1 (3%)		
Liver	(50)	(50)	(50)	(50)
Cholangioma, Multiple				1 (2%)
Hemangioma		1 (2%)		
Hemangiosarcoma	5 (10%)	4 (8%)	3 (6%)	1 (2%)
Hepatoblastoma	3 (6%)	5 (10%)	9 (18%)	4 (8%)
Hepatoblastoma, Multiple	3 (6%)	1 (2%)	2 (4%)	
Hepatocellular Adenoma	12 (24%)	11 (22%)	11 (22%)	15 (30%)
Hepatocellular Adenoma, Multiple	21 (42%)	30 (60%)	29 (58%)	20 (40%)
Hepatocellular Carcinoma	20 (40%)	13 (26%)	17 (34%)	15 (30%)
Hepatocellular Carcinoma, Multiple	6 (12%)	10 (20%)	9 (18%)	8 (16%)
Hepatocholangiocarcinoma	2 (4%)	2 (4%)	1 (2%)	
Ito Cell Tumor Malignant		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Sarcoma		1 (2%)		
Mesentery	(7)	(1)	(1)	(1)
Hepatocellular Carcinoma, Metastatic, Liver	1 (14%)			
Pancreas	(49)	(48)	(48)	(49)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Sarcoma, Metastatic, Liver		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(47)	(47)	(47)	(47)
Hemangioma		1 (2%)		
Squamous Cell Carcinoma			1 (2%)	
Squamous Cell Papilloma		1 (2%)		3 (6%)
Stomach, Glandular	(42)	(45)	(43)	(45)
Tooth	(35)	(41)	(42)	(41)

CARDIOVASCULAR SYSTEM

Heart	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)	1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver		2 (4%)	2 (4%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Sarcoma, Metastatic, Liver		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			

ENDOCRINE SYSTEM

Adrenal Cortex	(49)	(48)	(50)	(48)
Adenoma			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
Sarcoma, Metastatic, Liver		1 (2%)		
Subcapsular, Adenoma	2 (4%)	1 (2%)	5 (10%)	3 (6%)
Adrenal Medulla	(49)	(47)	(50)	(48)
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
Islets, Pancreatic	(49)	(48)	(48)	(49)
Adenoma	1 (2%)		1 (2%)	
Parathyroid Gland	(37)	(39)	(44)	(31)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Pituitary Gland	(47)	(49)	(49)	(49)
Pars Distalis, Adenoma			1 (2%)	
Thyroid Gland	(49)	(50)	(49)	(49)
Follicular Cell, Adenoma	1 (2%)			
Follicular Cell, Carcinoma		1 (2%)		

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Coagulating Gland	(2)	(0)	(0)	(0)
Epididymis	(50)	(50)	(50)	(49)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			
Preputial Gland	(50)	(50)	(50)	(50)
Prostate	(50)	(50)	(48)	(50)
Seminal Vesicle	(47)	(48)	(49)	(47)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			
Testes	(50)	(50)	(50)	(50)
Interstitial Cell, Adenoma		1 (2%)	1 (2%)	1 (2%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(48)	(50)
Hemangiosarcoma	2 (4%)			2 (4%)
Lymph Node	(2)	(1)	(0)	(2)
Mediastinal, Hemangiosarcoma				1 (50%)
Mediastinal, Hepatoblastoma, Metastatic, Liver		1 (100%)		
Mediastinal, Hepatocellular Carcinoma, Metastatic, Liver				1 (50%)
Mediastinal, Hepatocholangiocarcinoma, Metastatic, Liver	1 (50%)			
Lymph Node, Mandibular	(50)	(49)	(49)	(50)
Carcinoma, Metastatic, Harderian Gland		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Hepatocellular Carcinoma, Metastatic, Liver				1 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle	1 (2%)			
Lymph Node, Mesenteric	(45)	(45)	(43)	(45)
Sarcoma, Metastatic, Liver		1 (2%)		
Spleen	(46)	(48)	(47)	(46)
Hemangiosarcoma	1 (2%)	1 (2%)	2 (4%)	2 (4%)
Thymus	(41)	(42)	(48)	(47)
Hemangiosarcoma, Metastatic, Liver		1 (2%)		
Hepatoblastoma, Metastatic, Liver			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)	1 (2%)		
Sarcoma, Metastatic, Liver		1 (2%)		

INTEGUMENTARY SYSTEM

Skin	(50)	(50)	(50)	(50)
Subcutaneous Tissue, Fibrous Histiocytoma	1 (2%)	2 (4%)		1 (2%)
Subcutaneous Tissue, Hemangioma	1 (2%)			1 (2%)
Subcutaneous Tissue, Hemangiosarcoma	1 (2%)		2 (4%)	1 (2%)
Subcutaneous Tissue, Lipoma			1 (2%)	1 (2%)
Subcutaneous Tissue, Sarcoma		1 (2%)		

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(50)
Chondrosarcoma			1 (2%)	
Skeletal Muscle	(1)	(0)	(0)	(0)
Rhabdomyosarcoma	1 (100%)			

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)
Sarcoma, Metastatic, Liver		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
------------------	--------	------------	----------	-----------

RESPIRATORY SYSTEM

	(50)	(50)	(50)	(50)
Lung				
Alveolar/Bronchiolar Adenoma	6 (12%)	11 (22%)	14 (28%)	6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple			2 (4%)	2 (4%)
Alveolar/Bronchiolar Carcinoma	9 (18%)	7 (14%)	8 (16%)	6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple		2 (4%)		3 (6%)
Carcinoma, Metastatic, Harderian Gland	1 (2%)			1 (2%)
Hemangiosarcoma	2 (4%)			
Hemangiosarcoma, Metastatic, Liver		1 (2%)		
Hepatoblastoma, Metastatic, Liver	2 (4%)		1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	14 (28%)	12 (24%)	12 (24%)	6 (12%)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)	1 (2%)	1 (2%)	
Rhabdomyosarcoma, Metastatic, Skeletal Muscle	1 (2%)			
Sarcoma, Metastatic, Liver		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Nose	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland				1 (2%)
Hemangiosarcoma	1 (2%)			
Pleura	(0)	(1)	(0)	(1)
Hepatocellular Carcinoma, Metastatic, Liver		1 (100%)		1 (100%)
Trachea	(47)	(49)	(45)	(49)

SPECIAL SENSES SYSTEM

	(36)	(39)	(43)	(40)
Eye				
Harderian Gland	(46)	(47)	(46)	(47)
Adenoma	5 (11%)	5 (11%)	3 (7%)	2 (4%)
Carcinoma	2 (4%)	4 (9%)	1 (2%)	3 (6%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(49)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)		2 (4%)	2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Sarcoma, Metastatic, Liver		1 (2%)		
Renal Tubule, Adenoma, Multiple				1 (2%)
Renal Tubule, Carcinoma			1 (2%)	
Urethra	(3)	(3)	(5)	(3)
Urinary Bladder	(45)	(45)	(45)	(46)
SYSTEMIC LESIONS				
Multiple Organ	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma		1 (2%)		
Lymphoma Malignant		3 (6%)	2 (4%)	
Mesothelioma Benign	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
------------------	--------	------------	----------	-----------

Tumor Summary for Males

Total Animals with Primary Neoplasms (b)	48	50	48	46
Total Primary Neoplasms	112	124	128	105
Total Animals with Benign Neoplasms	36	44	44	43
Total Benign Neoplasms	49	63	69	58
Total Animals with Malignant Neoplasms	36	40	38	32
Total Malignant Neoplasms	62	61	59	47
Total Animals with Metastatic Neoplasms	19	16	14	7
Total Metastatic Neoplasms	32	31	23	15
Total Animals with Malignant Neoplasms Uncertain Primary Site	1			
Total Animals with Neoplasms Uncertain- Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
--------------------	--------	------------	----------	-----------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	4	3	1	4
Natural Death	8	15	14	13
Survivors				
Natural Death			1	
Terminal Sacrifice	38	32	34	33
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(49)	(49)	(50)
Gallbladder	(43)	(36)	(36)	(35)
Hepatoblastoma, Metastatic, Liver		1 (3%)		
Intestine Large, Cecum	(44)	(36)	(38)	(39)
Carcinoma			1 (3%)	
Intestine Large, Colon	(44)	(35)	(40)	(38)
Intestine Large, Rectum	(43)	(35)	(37)	(38)
Intestine Small, Duodenum	(42)	(35)	(36)	(37)
Intestine Small, Ileum	(44)	(36)	(37)	(37)
Intestine Small, Jejunum	(43)	(35)	(37)	(38)
Carcinoma				2 (5%)
Liver	(49)	(50)	(50)	(50)
Hemangiosarcoma	2 (4%)	5 (10%)	3 (6%)	2 (4%)
Hepatoblastoma	1 (2%)	3 (6%)	3 (6%)	3 (6%)
Hepatoblastoma, Multiple			1 (2%)	1 (2%)
Hepatocellular Adenoma	11 (22%)	3 (6%)	10 (20%)	9 (18%)
Hepatocellular Adenoma, Multiple	27 (55%)	43 (86%)	36 (72%)	30 (60%)
Hepatocellular Carcinoma	6 (12%)	13 (26%)	16 (32%)	18 (36%)
Hepatocellular Carcinoma, Multiple	5 (10%)	7 (14%)	10 (20%)	5 (10%)
Mast Cell Tumor Malignant		1 (2%)		
Osteosarcoma, Metastatic, Bone				1 (2%)
Rhabdomyosarcoma, Metastatic, Uncertain Primary Site			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Mesentery	(8)	(16)	(16)	(9)
Lipoma			1 (6%)	
Rhabdomyosarcoma, Metastatic, Uncertain Primary Site			1 (6%)	
Sarcoma				1 (11%)
Pancreas	(48)	(42)	(46)	(45)
Rhabdomyosarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Sarcoma, Metastatic, Mesentery				1 (2%)
Salivary Glands	(50)	(47)	(47)	(50)
Stomach, Forestomach	(47)	(43)	(45)	(47)
Squamous Cell Carcinoma		1 (2%)		
Squamous Cell Papilloma		1 (2%)	1 (2%)	1 (2%)
Stomach, Glandular	(45)	(39)	(41)	(41)
Tongue	(0)	(0)	(0)	(1)
Squamous Cell Carcinoma				1 (100%)
Tooth	(0)	(1)	(2)	(9)
Gingiva, Fibroma, Osseous		1 (100%)		

CARDIOVASCULAR SYSTEM

Blood Vessel	(2)	(3)	(1)	(0)
Heart	(50)	(50)	(49)	(50)
Hemangiosarcoma				1 (2%)
Pericardium, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)

ENDOCRINE SYSTEM

Adrenal Cortex	(49)	(45)	(46)	(50)
Adenoma				1 (2%)
Sarcoma, Metastatic, Mesentery				1 (2%)
Adrenal Medulla	(49)	(45)	(46)	(50)
Pheochromocytoma Benign	1 (2%)	1 (2%)		
Pheochromocytoma Complex			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Pheochromocytoma Malignant		2 (4%)		
Islets, Pancreatic	(48)	(41)	(45)	(45)
Adenoma		1 (2%)		1 (2%)
Parathyroid Gland	(38)	(34)	(40)	(41)
Pituitary Gland	(50)	(46)	(47)	(46)
Pars Distalis, Adenoma	4 (8%)	5 (11%)	2 (4%)	3 (7%)
Thyroid Gland	(48)	(45)	(45)	(49)
Follicular Cell, Adenoma				1 (2%)

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Clitoral Gland	(50)	(50)	(48)	(50)
Ovary	(49)	(48)	(48)	(47)
Cystadenoma	3 (6%)	4 (8%)		6 (13%)
Hemangioma				1 (2%)
Uterus	(49)	(47)	(49)	(49)
Hemangiosarcoma				1 (2%)
Polyp Stromal	2 (4%)			
Cervix, Sarcoma			1 (2%)	
Endometrium, Adenoma	1 (2%)			

HEMATOPOIETIC SYSTEM

Bone Marrow	(49)	(46)	(48)	(49)
Hemangiosarcoma	1 (2%)			
Mast Cell Tumor Malignant		1 (2%)		
Lymph Node	(6)	(8)	(6)	(8)
Bronchial, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (13%)
Iliac, Mast Cell Tumor Malignant		1 (13%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Iliac, Sarcoma, Metastatic, Mesentery				1 (13%)
Lumbar, Hemangiosarcoma		1 (13%)		
Mediastinal, Sarcoma, Metastatic, Mesentery				1 (13%)
Renal, Hemangiosarcoma		1 (13%)		
Lymph Node, Mandibular	(48)	(42)	(47)	(47)
Sarcoma, Metastatic, Mesentery				1 (2%)
Lymph Node, Mesenteric	(46)	(38)	(45)	(46)
Sarcoma, Metastatic, Mesentery				1 (2%)
Spleen	(46)	(42)	(45)	(46)
Fibrosarcoma				1 (2%)
Hemangiosarcoma	1 (2%)	2 (5%)		
Mast Cell Tumor Malignant		1 (2%)		
Thymus	(45)	(44)	(48)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		2 (4%)
Hemangiosarcoma			1 (2%)	
Rhabdomyosarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Sarcoma, Metastatic, Mesentery				1 (2%)

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(49)	(49)	(48)
Carcinoma		1 (2%)		
Skin	(50)	(50)	(50)	(50)
Mast Cell Tumor Benign	1 (2%)			
Subcutaneous Tissue, Fibrous Histiocytoma		1 (2%)		
Subcutaneous Tissue, Hemangiosarcoma	2 (4%)	1 (2%)		
Subcutaneous Tissue, Rhabdomyosarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Subcutaneous Tissue, Sarcoma	2 (4%)	2 (4%)	4 (8%)	4 (8%)

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(50)
------	------	------	------	------

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Osteosarcoma	2 (4%)			
Osteosarcoma, Multiple				1 (2%)
Skeletal Muscle	(1)	(0)	(0)	(1)
Sarcoma, Metastatic, Mesentery				1 (100%)

NERVOUS SYSTEM

Brain	(50)	(47)	(47)	(50)
Peripheral Nerve	(1)	(0)	(0)	(1)
Spinal Cord	(1)	(0)	(0)	(1)

RESPIRATORY SYSTEM

Lung	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Adenoma	5 (10%)	5 (10%)	4 (8%)	10 (20%)
Alveolar/Bronchiolar Adenoma, Multiple		1 (2%)		1 (2%)
Alveolar/Bronchiolar Carcinoma	7 (14%)	6 (12%)	8 (16%)	9 (18%)
Alveolar/Bronchiolar Carcinoma, Multiple		2 (4%)	2 (4%)	4 (8%)
Carcinoma, Metastatic, Harderian Gland	1 (2%)		3 (6%)	
Hepatoblastoma, Metastatic, Liver				1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)	5 (10%)	8 (16%)	4 (8%)
Mast Cell Tumor Malignant		1 (2%)		
Osteosarcoma, Metastatic, Bone				1 (2%)
Sarcoma, Metastatic, Mesentery				1 (2%)
Sarcoma, Metastatic, Skin	1 (2%)		1 (2%)	
Nose	(49)	(44)	(49)	(47)
Pleura	(0)	(0)	(0)	(1)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (100%)
Trachea	(47)	(41)	(45)	(44)

SPECIAL SENSES SYSTEM

Eye	(43)	(35)	(36)	(39)
-----	------	------	------	------

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Carcinoma, Metastatic, Harderian Gland	1 (2%)			
Harderian Gland	(45)	(41)	(43)	(47)
Adenoma	2 (4%)		2 (5%)	2 (4%)
Carcinoma	2 (4%)	1 (2%)	4 (9%)	4 (9%)
Bilateral, Carcinoma		1 (2%)		
Zymbal's Gland	(0)	(0)	(0)	(1)
URINARY SYSTEM				
Kidney	(49)	(47)	(48)	(49)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Mast Cell Tumor Malignant		1 (2%)		
Osteosarcoma, Metastatic, Bone				1 (2%)
Renal Tubule, Adenoma				1 (2%)
Urinary Bladder	(44)	(37)	(39)	(41)
SYSTEMIC LESIONS				
Multiple Organ	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)		1 (2%)	1 (2%)
Lymphoma Malignant	14 (28%)	15 (30%)	10 (20%)	13 (26%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

beta-Picoline

Time Report Requested: 09:52:35

Route: DOSED WATER

CAS Number: 108-99-6

First Dose M/F: 11/09/04 / 11/08/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
--------------------	--------	------------	----------	-----------

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	43	49	50	47
Total Primary Neoplasms	103	136	122	139
Total Animals with Benign Neoplasms	40	48	47	44
Total Benign Neoplasms	57	65	56	67
Total Animals with Malignant Neoplasms	29	42	41	41
Total Malignant Neoplasms	46	71	66	72
Total Animals with Metastatic Neoplasms	3	7	12	7
Total Metastatic Neoplasms	4	7	17	23
Total Animals with Malignant Neoplasms Uncertain Primary Site			1	
Total Animals with Neoplasms Uncertain- Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors